Literature DB >> 31758179

Live Attenuated Vaccine With a Stabilized Mutation and Gene Deletion for Prevention of Respiratory Syncytial Virus Disease in Young Children.

Michael N Teng1,2, Asuncion Mejias3,4,5,6, Octavio Ramilo3,4,5, Mark E Peeples3,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31758179      PMCID： PMC6996857          DOI： 10.1093/infdis/jiz604

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  12 in total

1.  The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription.

Authors:  A Bermingham; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030ΔSH) at permissive and non-permissive temperatures.

Authors:  Jeanne H Schickli; Jasmine Kaur; Roderick S Tang
Journal:  Virus Res       Date:  2012-07-04       Impact factor: 3.303

3.  Risk of childhood wheeze and asthma after respiratory syncytial virus infection in full-term infants.

Authors:  Asuncion Mejias; Bingcao Wu; Neeta Tandon; Wing Chow; Ram Varma; Eduardo Franco; Octavio Ramilo
Journal:  Pediatr Allergy Immunol       Date:  2019-10-23       Impact factor: 6.377

4.  Temperature-sensitive mutants of respiratory syncytial virus.

Authors:  M A Gharpure; P F Wright; R M Chanock
Journal:  J Virol       Date:  1969-04       Impact factor: 5.103

5.  Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

Authors:  S S Whitehead; C Y Firestone; R A Karron; J E Crowe; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

7.  Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.

Authors:  Elizabeth J McFarland; Ruth A Karron; Petronella Muresan; Coleen K Cunningham; Jennifer Libous; Charlotte Perlowski; Bhagvanji Thumar; Devasena Gnanashanmugam; Jack Moye; Elizabeth Schappell; Emily Barr; Vivian Rexroad; Laura Fearn; Stephen A Spector; Mariam Aziz; Mikhaela Cielo; Christy Beneri; Andrew Wiznia; Cindy Luongo; Peter Collins; Ursula J Buchholz
Journal:  J Infect Dis       Date:  2020-02-03       Impact factor: 5.226

8.  A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.

Authors:  Ruth A Karron; Cindy Luongo; Bhagvanji Thumar; Karen M Loehr; Janet A Englund; Peter L Collins; Ursula J Buchholz
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

9.  Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Authors:  Elissa Malkin; Ram Yogev; Nazha Abughali; Joseph Sliman; C Kathy Wang; Fengrong Zuo; Chin-Fen Yang; Mark Eickhoff; Mark T Esser; Roderick S Tang; Filip Dubovsky
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

10.  Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated.

Authors:  Coleen K Cunningham; Ruth Karron; Petronella Muresan; Elizabeth J McFarland; Charlotte Perlowski; Jennifer Libous; Bhagvanji Thumar; Devasena Gnanashanmugam; Jack Moye; Elizabeth Schappell; Emily Barr; Vivian Rexroad; Mariam Aziz; Jaime Deville; Richard Rutstein; Lijuan Yang; Cindy Luongo; Peter Collins; Ursula Buchholz
Journal:  Open Forum Infect Dis       Date:  2019-05-06       Impact factor: 3.835
View more
  2 in total

1.  TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO).

Authors:  Federico Martinón-Torres; Adolfo García-Sastre; Andrew J Pollard; Carlos Martín; Albert Osterhaus; Shamez N Ladhani; Octavio Ramilo; Jose Gómez Rial; Antonio Salas; F Xavier Bosch; María Martinón-Torres; Michael J Mina; James Cherry
Journal:  Hum Vaccin Immunother       Date:  2021-11-11       Impact factor: 3.452

Review 2.  Evaluation of the Safety and Immune Efficacy of Recombinant Human Respiratory Syncytial Virus Strain Long Live Attenuated Vaccine Candidates.

Authors:  Li-Nan Wang; Xiang-Lei Peng; Min Xu; Yuan-Bo Zheng; Yue-Ying Jiao; Jie-Mei Yu; Yuan-Hui Fu; Yan-Peng Zheng; Wu-Yang Zhu; Zhong-Jun Dong; Jin-Sheng He
Journal:  Virol Sin       Date:  2021-02-09       Impact factor: 4.327
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.